My research investigates the epigenetic landscape surrounding T-cell lineage restriction in normal and leukemic T-cell development by using our lab’s well-established cord blood transduction protocols, genomic assays, and spectral flow cytometry. We hope to understand how the aberrant expression of epigenetic modifiers (e.g. DNMT3A) can contribute to the pathogenesis of T-ALL, particularly in subtypes that co-express myeloid markers, such as ETP-ALL.

Back to top